Unimolecular GLP1R/GIPR dual agonists not only amplify the metabolic benefits of GLP-1 therapies but may also reduce common side effects, offering an effective strategy for managing obesity and T2D-related conditions (57, 58). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.